These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8879560)

  • 21. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
    Thompson WJ; Fitzgerald PM; Holloway MK; Emini EA; Darke PL; McKeever BM; Schleif WA; Quintero JC; Zugay JA; Tucker TJ
    J Med Chem; 1992 May; 35(10):1685-701. PubMed ID: 1588551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.
    Takashiro E; Hayakawa I; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Yamamoto I; Shibayama T; Nakagawa A; Yabe Y
    Bioorg Med Chem; 1999 Sep; 7(9):2063-72. PubMed ID: 10530956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
    Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
    Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid.
    Komai T; Yagi R; Suzuki-Sunagawa H; Sakurai M; Higashida S; Sugano M; Handa H; Mohri H; Yasuoka A; Oka S; Yabe Y; Nishigaki T; Kimura S; Shimada K
    Biol Pharm Bull; 1997 Feb; 20(2):175-80. PubMed ID: 9057982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of HIV-1 protease by oxim derivatives.
    Komai T; Yagi R; Suzuki-Sunagawa H; Ishikawa Y; Kasuya A; Miyamoto S; Handa H; Nishigaki T
    Biochem Biophys Res Commun; 1997 Jan; 230(3):557-61. PubMed ID: 9015361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere.
    Rutenber EE; McPhee F; Kaplan AP; Gallion SL; Hogan JC; Craik CS; Stroud RM
    Bioorg Med Chem; 1996 Sep; 4(9):1545-58. PubMed ID: 8894111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
    Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.